Format

Send to

Choose Destination
J Invest Dermatol. 2006 Apr;126(4):708-10.

Fibroblasts as target cells for DEB gene therapy.

Author information

1
Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.

Abstract

Dystrophic epidermolysis bullosa (DEB) is due to mutations in the type VII collagen (C7) gene. Potential therapies for DEB include (i) ex vivo gene therapy and (ii) intradermal injection of gene-corrected DEB fibroblasts, lentiviral vectors expressing C7 or recombinant C7 itself. With regard to molecular engineering, the dermal fibroblast has advantages over epidermal keratinocytes for delivering C7 to DEB patients.

PMID:
16541096
DOI:
10.1038/sj.jid.5700216
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center